Antitope, a PolyTherics company, entered a research agreement with Annexon to generate antibody therapeutics for the treatment of neurodegenerative diseases.

As part of the agreement, Annexon will provide antibodies against specific components of the complement system and Antitope will use its Composite Human Antibody™ technology to generate a series of fully humanized antibodies devoid of T cell epitopes and with a consequent low risk of clinical immunogenicity. Annexon will screen the Composite Human Antibodies provided by Antitope and select a lead antibody to take forward into further preclinical and clinical studies. According to the company, Annexon’s most advanced program is for an orphan autoimmune neurological indication. The antibodies are expected to halt the progression of disease and allow the body to repair.

“This further agreement for Antitope’s Composite Human Antibody™ technology provides another opportunity for our technology to produce a better biopharmaceutical for the treatment of patients who despite years of research are still not receiving adequate treatment for their disease,” said Matt Baker, CSO of the PolyTherics group.

PolyTherics merged with Antitope in July to create a combined provider of services and technologies for biopharmaceutical development.

Previous articleNovo Nordisk Faces Police Probe over Disclosure Delay
Next articleTau Mouse Models for Alzheimer’s Research Focus of Taconic, Oligomerix Pact